Functional Concept
Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy
Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials
BridgeBio’s Infigratinib Demonstrates Sustained Efficacy in Phase 2 Trial for Achondroplasia Treatment
BridgeBio, Infigratinib, Achondroplasia, Hypochondroplasia, Phase 2 Trial, Growth Disorder Treatment
ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment
ASCO 2024, Opdivo-Yervoy, Bristol Myers Squibb, Liver Cancer, First-Line Treatment, Roche, AstraZeneca, Immunotherapy, CheckMate-9DW
Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO
Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment
Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy
Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data
AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment
Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment
BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati
Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA
Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data
Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor
FDA Delays Dupixent Decision for Uncontrolled COPD Treatment, EU Panel Recommends Approval
Dupixent, dupilumab, COPD, FDA, EU approval, Sanofi, Regeneron, uncontrolled COPD, treatment delay
Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###
Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies